Incyte Corporation
Every calculator, already run for INCY
Open the full toolkit →You have the numbers on INCY. Get the argument.
A written report on which of these readings actually decide the outcome for Incyte Corporation, what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
28 analysts covering INCYAnalyst Price Target Disagreement for Incyte Corporation
Wall Street's bull case implies +24% from the current price; the bear case implies -31%. A 55% spread signals high analyst disagreement — run your own DCF to anchor on fundamentals rather than street consensus.
Ownership & short interest
Insider Trading Activity for INCY
| Insider | Role | Type | Shares | Price | Value | Date | Filing |
|---|---|---|---|---|---|---|---|
About Incyte Corporation
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI for the treatment of myelofibrosis (MF), polycythemia vera, and steroid-refractory acute graft-versus-host disease; ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; MONJUVI/ MINJUVI for the treatment of diffuse large B-cell lymphoma and Follicular Lymphoma; NIKTIMVO for the treatment of chronic graft-versus-host disease. It also provides INCA033989 for the treatment of essential thrombocythemia and MF; INCA035784 f…
INCY — frequently asked
Is INCY a buy right now?
Wall Street's consensus rating on Incyte Corporation is Buy across 28 analysts, with a mean price target of $127.74 (+2% vs. the current $125.42). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
Is INCY overvalued?
INCY trades at 16.0x trailing earnings, against a DCF fair value of $138 per share. The current price implies 5% annual free-cash-flow growth for a decade. Open the DCF or reverse-DCF tool to change the assumptions and see the range.
When is INCY's next earnings date?
Incyte Corporation is next scheduled to report earnings around Oct 27, 2026. A full INCY research report from Basis Report covers the setup into that print — estimates, the beat/miss record, and what would move the thesis.
What is the analyst price target disagreement for Incyte Corporation?
Analysts covering Incyte Corporation (INCY) range from a bear-case target of $86.00 to a bull-case high of $155.00, with a mean consensus target of $127.74 across 23 analysts. The spread of $69.00 (55% of the current price) indicates high disagreement on the outlook. Run the DCF calculator to build your own estimate independent of street consensus.
Compare Incyte Corporation against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For Incyte Corporation
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full INCY research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on Incyte Corporation, in minutes. 3 free reports included with every account — no credit card required.